ReviewBioactive materials2026
Inhaled formulations for bacterial pneumonia: Strategies and advances in drug delivery.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled formulations have garnered significant interest in the treatment of bacterial pneumonia, as they deliver the drug directly to the site of infection in the lungs, providing high local drug concentrations that are typically unattainable with oral or intravenous therapies. Technologies for inhalation formulations that enable efficient sterilization, effective nebulization, maximized lung deposition, and reduced macrophage uptake are critical for successful inhaled drug delivery. Consequently, formulation strategies for inhalation drug delivery aimed at treating bacterial pneumonia are of paramount importance, encompassing factors such as the selection of bactericidal agents, drug carriers, aerodynamic diameter of particles, and particle morphology. The appropriate selection of formulation strategies is essential to overcoming the barriers of the respiratory tract, reaching the infected sites, releasing the bactericides, and penetrating deep into the biofilm to achieve effective eradication of bacterial pneumonia. This paper aims to classify recent inhaled preparations for bacterial pneumonia and to provide insights and perspectives for the development of novel inhaled delivery formulations targeting this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.